GENEVA, Switzerland, March 21 /PRNewswire-FirstCall/ -- Merck Serono
S.A. (virt-x: SEO and NYSE: SRA) announced today that the preliminary
fourth quarter and full-year consolidated results for the period ended
December 31, 2006, which were published on March 1, 2007, are confirmed.
    The audited detailed consolidated financial statements are appended.
They have been prepared on the basis of International Financial Reporting
Standards. The accompanying notes to these 2006 full-year consolidated
financial statements will be available upon the release of Merck Serono's
2006 Annual Report by end April 2007.
    Forward-looking statements
    Some of the statements in this press release are forward looking. Such
statements are inherently subject to known and unknown risks, uncertainties
and other factors that may cause actual results, performance or
achievements of Merck Serono S.A. and affiliates to be materially different
from those expected or anticipated in the forward-looking statements.
Forward-looking statements are based on Merck Serono's current expectations
and assumptions, which may be affected by a number of factors, including
those discussed in this press release and more fully described in Serono's
Annual Report on Form 20-F filed with the U.S. Securities and Exchange
Commission on February 28, 2006. These factors include any failure or delay
in Merck Serono's ability to develop new products, any failure to receive
anticipated regulatory approvals, any problems in commercializing current
products as a result of competition or other factors, our ability to obtain
reimbursement coverage for our products, the outcome of any government
investigations and litigation. Merck Serono is providing this information
as of the date of this press release, and has no responsibility to update
the forward-looking statements contained in this press release to reflect
events or circumstances occurring after the date of this press release.
    About Merck Serono S.A.
    Merck Serono S.A. is a global biotechnology leader, with sales in over
90 countries. The Company is the world leader in reproductive health, with
Gonal-f(R), Luveris(R) and Ovidrel(R)/Ovitrelle(R). It has strong market
positions in neurology, with Rebif(R), as well as in metabolism and growth,
with Saizen(R), Serostim(R) and Zorbtive(TM). The Company has recently
entered the psoriasis area with Raptiva(R). Merck Serono's research
programs are focused on growing these businesses and on establishing new
therapeutic areas, including oncology and autoimmune diseases.
    Bearer shares of Merck Serono S.A., the holding company, are traded on
the virt-x (SEO) and its American Depositary Shares are traded on the New
York Stock Exchange (SRA).
    About Merck
    Merck is a global pharmaceutical and chemical company with sales of EUR
6.3 billion in 2006, a history that began in 1668, and a future shaped by
about 35,000 employees (including Merck Serono) in 56 countries. Its
success is characterized by innovations from entrepreneurial employees.
Merck's operating activities come under the umbrella of Merck KGaA, in
which the Merck family holds a 70% interest and free shareholders own the
remaining 30%. In 1917 the U.S. subsidiary Merck & Co. was expropriated and
has been an independent company ever since.
    A full version of this release, including tables, is available at
http://www.merckserono.net

Link to this page: